Skip to main content

Table 4 Partial list of commercially available circulating tumor markers for urologic malignancies

From: Liquid biopsy: a step forward towards precision medicine in urologic malignancies

Test name Molecules assessed Cancer type Clinical application Biological fluid tested Reference
CELLSEARCH® CTC Test CTCa Prostate Prognostic for patients with metastatic prostate cancer Blood [44]
PROGENSA PCA3 Test lncRNA PCA3 Prostate Diagnostic for prostate cancer patients with previous negative biopsy (Determine need for repeat biopsy) Urine [73]
Prostate Health Index (PHI) Protein (total PSA, free PSA, and [-2] proPSA) Prostate Diagnostic for prostate cancer patients with a PSA between 4 and 10 ng/mL Blood [94]
4KScore Protein (total PSA, free PSA, intact PSA, and human KLK 2) Prostate Prognostic (Assess risk for aggressive prostate cancer) Blood [95]
ImmunoCyt™ Test Protein (mucins and HMW carcinoembryonic antigen) Bladder Diagnostic for G1, G2 and G3 bladder cancer patients with positive urine cytology Urine [96]
Aura Tek FDP Test™ Protein (fibrin degradation product) Bladder Predictive of bladder cancer recurrence Urine [97]
ExoDx Prostate (IntelliScore) Exosomal RNA Prostate Prognostic for high-grade prostate cancer at the time of biopsy and at surgery Urine [117]
  1. aCirculating tumor cell